Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease (KAPA)

This study has been completed.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00549601
First received: October 24, 2007
Last updated: February 24, 2011
Last verified: February 2011

October 24, 2007
February 24, 2011
September 2007
April 2009   (final data collection date for primary outcome measure)
Percentage of Patients Who Had a Gastrointestinal Adverse Event (AE) at Any Time During the Study [ Time Frame: Baseline to end of study (Month 3) ] [ Designated as safety issue: Yes ]
Gastrointestinal adverse events (including nausea, vomiting, and diarrhea) were coded using the medical dictionary MedDRA v11.0 and the number of patients who suffered an AE were described by system organ class (SOC) and preferred term (PT).
The mean incidence of gastrointestinal adverse events at all visits during the study between the two study groups.
Complete list of historical versions of study NCT00549601 on ClinicalTrials.gov Archive Site
  • Percentage of Patients With an AE Involving the Skin (Local Tolerance) Recorded Over the Course of the Study Period (Patch Groups Only) [ Time Frame: Baseline to end of study (Month 3) ] [ Designated as safety issue: Yes ]
    Adverse events involving the skin included urticaria, pruritus, erythema, and pigmentation disorder. Only the groups administered rivastigmine transdermally via patch were analyzed. The adverse events were coded using the medical dictionary MedDRA v11.0 and the number of patients who suffered an AE were described by system organ class (SOC) and preferred term (PT).
  • Percentage of Patients With at Least 1 AE of Any Kind Recorded During the Period of the Study. [ Time Frame: Baseline to end of study (Month 3) ] [ Designated as safety issue: Yes ]
    Adverse events were coded using the medical dictionary MedDRA v11.0 and the number of patients who suffered an AE were described by system organ class (SOC) and preferred term (PT). They were also tabulated by severity, relationship with study treatment, and action taken.
  • Overall Caregiver Satisfaction With Treatment [ Time Frame: At end of study (Month 3) ] [ Designated as safety issue: No ]
    Caregivers were asked to rate their overall degree of satisfaction with the Alzheimer's disease treatment on a scale of 1 to 5 (1 "Very good" - 5 "Very poor") at the end of the study (Month 3). A higher score indicates less satisfaction.
  • Overall Patient Satisfaction With Treatment [ Time Frame: At end of study (Month 3) ] [ Designated as safety issue: No ]
    Patients were asked to rate their overall degree of satisfaction with the Alzheimer's disease treatment on a scale of 1 to 5 (1 "Very good" - 5 "Very poor") at the end of the study (Month 3). A higher score indicates less satisfaction.
  • Change in the Total Mini-Mental State Examination (MMSE) Score From Baseline to Month 1 and Month 3 [ Time Frame: Baseline to Month 1 and Month 3 ] [ Designated as safety issue: No ]
    The Mini Mental State Examination (MMSE) was used to evaluate the patient's cognitive status and how it progressed over time. The 35-point version used in this study was made up of five sections: orientation, fixation, attention and calculation, memory and language, and constructional praxis. The total score for each patient was obtained by adding the score from each of the above sections. The individual receives 1 point for each correct answer. The total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement.
- The mean incidence of any adverse events at all visits during the study between the two study groups. - The mean incidence of skin adverse events at all visits during the study between the two study groups. - Caregiver / patient satisfaction with
Not Provided
Not Provided
 
Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
A Multi-center, Randomised, Open-label Study to Evaluate Convenience and Safety of Change in the Mode of Administration of Rivastigmine (From Capsules to a Transdermal Patch) in Patients With Alzheimer's Disease

This study used two doses of rivastigmine transdermal patch (5 cm^2, 10 cm^2) to establish the feasibility of 2 switch schedules (with transdermal patch one-step dose titration or without dose titration) from rivastigmine capsules (3 mg bid (bis in die, twice a day), 4,5 mg bid, 6 mg bid) to rivastigmine transdermal patch and to assess safety, tolerability, convenience, and caregivers preferences of rivastigmine transdermal patch versus capsules.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Alzheimer's Disease
  • Drug: Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)
    Rivastigmine administered transdermally via patches at increasing doses (1 patch/day of 4.6 mg for the first month, changing to 1 patch/day of 9.5 mg for the remaining two months).
  • Drug: Rivastigmine patch (9.5 mg/day)
    Rivastigmine administered transdermally via patches at a constant dose (9.5 mg/day for the 3 months of treatment).
  • Drug: Rivastigmine capsules (6 mg to 12 mg/day)
    Rivastigmine administered orally, following the same regime as prior to randomization (doses between 6 mg and 12 mg/day), which remained unchanged throughout the 3 months of treatment.
  • Experimental: Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)
    Intervention: Drug: Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)
  • Experimental: Rivastigmine patch (9.5 mg/day)
    Intervention: Drug: Rivastigmine patch (9.5 mg/day)
  • Active Comparator: Rivastigmine capsules (6 mg to 12 mg/day)
    Intervention: Drug: Rivastigmine capsules (6 mg to 12 mg/day)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
142
April 2009
April 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Meet DSM-IV (Diagnostic & Statistical Manual of Mental Disorders, Version IV) criteria for dementia of Alzheimer type and NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) criteria for probable Alzheimer's disease (AD), have a MMSE (Mini Mental State Examination) score > 10 and < 26
  • Have received continuous treatment with rivastigmine capsules at least with 3 mg bid (6 mg of total daily dose) for at least 3 months before entering in the study
  • Cooperative, willing to complete all aspects of the study, and capable of doing so, either alone or with the aid of a responsible caregiver
  • Have a primary caregiver willing to accept responsibility for supervising the treatment, (eg, application and removal of the patch daily at approximately the same time of day) and assessing the condition of the patient throughout the study.

Exclusion Criteria:

  • A medical or neurological condition other that AD that could explain the patients dementia (eg, Huntington's disease, Parkinson's Disease, abnormal thyroid function test, B12 or folate deficiency, post-traumatic conditions, syphilis)
  • Current diagnosis of an active skin lesion/disorder that would prevent accurate assessment of the adhesion and potential skin irritation of the patch (e.g., atopic dermatitis, wounded or scratched skin in the area of the patch application)
  • History of allergy to topical products containing vitamin E
  • Taken any of the following substances prior to randomization:

    • succinylcholine-type muscle relaxants during the previous 2 weeks
    • an investigational drug during the previous 4 weeks

Other protocol-defined inclusion/exclusion criteria applied to the study.

Both
60 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT00549601
CENA713DES07
Not Provided
External Affairs, Novartis
Novartis
Not Provided
Study Director: Novartis Pharmaceuticals, MD Novartis Pharmaceuticals
Novartis
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP